TD Cowen Raises HCA Healthcare (HCA) Price Target to $460

TD Cowen has reiterated its Buy rating on HCA Healthcare, Inc. (NYSE: HCA) with a new price target of $460 on October 12, 2026. This is an increase from the previous target of $431. As of October 16, 2026, HCA shares were recently trading at $459.52, which is about equal to the new target, reflecting a minor 0.1% dip since the announcement.

Other Institutional Activity in HCA Healthcare

Several other institutional investors have adjusted their positions in HCA Healthcare recently. Blackrock Inc. reduced its holdings by 359,466 shares, bringing its total to 13,003,600 shares worth approximately $5.97 billion. Vanguard Capital Management LLC also trimmed its stake, decreasing by 36,642 shares, to a total of 10,141,708 shares valued at about $4.65 billion. Sanders Capital, LLC cut its position by 128,985 shares, ending with 8,828,287 shares worth around $4.05 billion, while State Street Corporation decreased its holdings by 70,875 shares to 7,469,035 shares valued at about $3.43 billion. In contrast, Wellington Management Group, LLP increased its stake by 799,884 shares, totaling 4,707,473 shares worth about $2.16 billion.

HCA Healthcare, Inc. Stock Up 7.4%

HCA Healthcare shares recently traded around $459.52, which is close to the new price target of $460 set by TD Cowen. This positioning suggests that the stock is trading effectively at the target level, with slight movement since the rating announcement.

Recent Earnings

HCA Healthcare reported a trailing twelve-month revenue of approximately $78.0 billion and an earnings per share (EPS) of $29.81. The company has a net margin of 8.8% and a revenue growth year-over-year of 8.7%. The next earnings report is scheduled for October 23, 2026.

Insider Buying and Selling at HCA Healthcare, Inc.

Recent insider transactions at HCA Healthcare include several officers selling shares. Michael S. Cuffe sold 1,500 shares at an average price of $498.09 on February 3, 2026, totaling about $747,135. On February 11, 2026, Jennifer Berres sold 8,020 shares valued at approximately $4.13 million, while Christopher F. Wyatt sold 4,000 shares for around $2.02 million at an average price of $505. In another transaction, Michael R. Mcalevey sold 1,694 shares at an average price of $533.37, amounting to about $903,537 on February 18, 2026.

Analysts Set New Price Targets

On October 12, 2026, TD Cowen maintained its Buy rating on HCA Healthcare with a new price target of $460. Earlier, on October 7, 2026, RBC Capital raised its target to $496 while maintaining an Outperform rating. Other firms, including BMO Capital and Leerink Partners, also recently reiterated their Outperform ratings with targets of $495 and $492, respectively.

About HCA Healthcare, Inc.

HCA Healthcare, Inc. provides healthcare services across the United States through its various subsidiaries. The company operates a network of hospitals and outpatient facilities, focusing on delivering quality medical care to patients. With a workforce of about 230,000 employees, HCA is a significant player in the healthcare industry.

Bottom Line

Investors should keep an eye on HCA Healthcare's upcoming earnings report on October 23, 2026, for further insights into the company's performance. TD Cowen's recent rating and target adjustment indicate confidence in the company's future prospects, alongside other analyst endorsements.